Abstract
Infections with hepatitis B virus (HBV) or hepatitis C virus (HCV) are associated with significant morbidity and mortality among patients with cancer, especially in patients with hematologic malignancies and those who undergo hematopoietic stem-cell transplantation. Reported rates of HBV reactivation in HBV carriers who undergo chemotherapy range from 14–72%. In these patients, mortality rates range from 5–52%. HCV reactivation seems to be less common than HBV reactivation and is usually associated with a good outcome and low mortality. However, once severe hepatitis develops, as a result of viral reactivation, mortality rates seem to be similar among patients infected with HBV or HCV. Liver damage owing to viral reactivation frequently leads to modifications or interruptions of chemotherapy, which can negatively affect patients' clinical outcome. Risk factors for the development of severe HBV or HCV reactivation need to be better defined to permit identification of patients who may benefit from preventive measures, early diagnosis, and therapy. In this article, we review the epidemiology, pathogenesis, risk factors, and clinical and laboratory manifestations associated with reactivation of HBV and HCV during immunosuppressive therapy. We also discuss strategies for the prevention and treatment of viral reactivation, including the management of reactivation with new antiviral agents.
Key Points
-
Patients with cancer who are at risk of infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) should undergo standard viral screening before initiation of cancer therapy
-
HBV-DNA levels and HCV-RNA levels should be measured in patients who are at high risk of viral reactivation
-
A substantial proportion of cancer patients with HBV or HCV infection develop liver dysfunction during chemotherapy, which often leads to discontinuation of potentially life-saving chemotherapy
-
Treatment with antiviral agents can effectively prevent HBV reactivation, should be initiated before cancer therapy, and maintained during as well as for 6–12 months after discontinuation of immunosuppressive therapy
-
HCV reactivation seems to be less frequent and less severe than HBV reactivation, but if severe hepatitis develops, mortality rates seem to be similar to those of HBV-infected patients
-
Treatment of HCV reactivation is mainly supportive and new agents for the treatment of patients with HCV reactivation are urgently needed
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Torres, H. A., Boeckh, M. & Chemaly, R. F. in Medical Care of Cancer Patients (eds Yeung, S. J., Escalante, C. & Gagel, R. F.) 151–161 (B. C. Decker Inc Publisher, Shelton, CT, 2009).
Lok, A. S. et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100, 182–188 (1991).
Law, J. K. et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk. Lymphoma 46, 1085–1089 (2005).
Alexopoulos, C. G., Vaslamatzis, M. & Hatzidimitriou, G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br. J. Cancer 81, 69–74 (1999).
Yeo, W. et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J. Clin. Oncol. 22, 927–934 (2004).
Liang, R., Lau, G. K. & Kwong, Y. L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J. Clin. Oncol. 17, 394–398 (1999).
Lalazar, G., Rund, D. & Shouval, D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br. J. Haematol. 136, 699–712 (2007).
Aksoy, S. et al. Rituximab-related viral infections in lymphoma patients. Leuk. Lymphoma 48, 1307–1312 (2007).
Lau, G. K. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol. Int. 2, 152–162 (2008).
Hoofnagle, J. H. Reactivation of hepatitis B. Hepatology 49 (Suppl. 5), S156–S165 (2009).
Mindikoglu, A. L., Regev, A. & Schiff, E. R. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin. Gastroenterol. Hepatol. 4, 1076–1081 (2006).
Xunrong, L., Yan, A. W., Liang, R. & Lau, G. K. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy—pathogenesis and management. Rev. Med. Virol. 11, 287–299 (2001).
Su, W. P. et al. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World J. Gastroenterol. 11, 5283–5288 (2005).
Yeo, W. et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br. J. Cancer 90, 1306–1311 (2004).
Yeo, W. et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 62, 299–307 (2000).
Yeo, W. et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J. Med. Virol. 70, 553–561 (2003).
Dai, M. S., Wu, P. F., Shyu, R. Y., Lu, J. J. & Chao, T. Y. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 24, 540–546 (2004).
Yeo, W. et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann. Oncol. 15, 1661–1666 (2004).
Jang, J. W. et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J. Hepatol. 41, 427–435 (2004).
Park, J. W. et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am. J. Gastroenterol. 100, 2194–2200 (2005).
Lau, G. K. et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 99, 2324–2330 (2002).
Iannitto, E. et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur. J. Haematol. 74, 254–258 (2005).
Targhetta, C., Cabras, M. G., Mamusa, A. M., Mascia, G. & Angelucci, E. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 93, 951–952 (2008).
Weinbaum, C. M. et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 57, 1–20 (2008).
Artz, A. S. et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J. Clin. Oncol. 28, 3199–3202 (2010).
Lau, G. K. et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125, 1742–1749 (2003).
Hsu, C. et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 47, 844–853 (2008).
Loomba, R. et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 148, 519–528 (2008).
Ziakas, P. D., Karsaliakos, P. & Mylonakis, E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 94, 998–1005 (2009).
Lok, A. S. & McMahon, B. J. Chronic hepatitis B. Hepatology 45, 507–539 (2007).
Hui, C. K. et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54, 1597–1603 (2005).
Yeo, W. & Johnson, P. J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43, 209–220 (2006).
Lau, G. K. et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36, 702–709 (2002).
Lok, A. S. et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125, 1714–1722 (2003).
European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 50, 227–242 (2009).
Evens, A. M. et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann. Oncol. 22, 1170–1180 (2011).
Onozawa, M. et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79, 616–619 (2005).
Kawatani, T. et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur. J. Haematol. 67, 45–50 (2001).
Ozguroglu, M., Bilici, A., Turna, H. & Serdengecti, S. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med. Oncol. 21, 67–72 (2004).
Markovic, S., Drozina, G., Vovk, M. & Fidler-Jenko, M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 46, 2925–2930 (1999).
Vento, S., Cainelli, F. & Longhi, M. S. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol. 3, 333–340 (2002).
Faggioli, P. et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica 82, 38–42 (1997).
Nosotti, L. et al. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy. Scand. J. Infect. Dis. http://dx.doi.org/10.3109/00365548.2011.611819.
Takai, S. et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur. J. Haematol. 74, 158–165 (2005).
de Pree, C., Giostra, E., Galetto, A., Perrin, L. & Zulian, G. B. Hepatitis C virus acute exacerbation during chemotherapy and radiotherapy for oesophageal carcinoma. Ann. Oncol. 5, 861–862 (1994).
Melisko, M. E., Fox, R. & Venook, A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin. Oncol. (R. Coll. Radiol.) 16, 204–205 (2004).
Fan, F. S. et al. Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C. Bone Marrow Transplant. 8, 417–420 (1991).
Kanamori, H. et al. Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am. J. Med. Sci. 303, 109–111 (1992).
Zuckerman, E., Zuckerman, T., Douer, D., Qian, D. & Levine, A. M. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 83, 1224–1230 (1998).
Mahale P. et al. Acute exacerbation of chronic hepatitis C in cancer patients. Presented at the 48th Annual Meeting of the Infectious Diseases Society of America (Vancouver, Canada, 2010).
Vento, S. et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 347, 92–93 (1996).
Nakamura, Y., Motokura, T., Fujita, A., Yamashita, T. & Ogata, E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer 78, 2210–2215 (1996).
Locasciulli, A. et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant. 31, 295–300 (2003).
Hamaguchi, M. et al. Retrospective study on the impact of hepatitis B and hepatitis C virus infection on hematopoietic stem cell transplantation in Japan. Int. J. Hematol. 75, 324–331 (2002).
Turner, N. C., Dusheiko, G. & Jones, A. Hepatitis C and B-cell lymphoma. Ann. Oncol. 14, 1341–1345 (2003).
Nicot, F. et al. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl. Int. 23, 594–601 (2010).
McGovern, B. H. et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin. Infect. Dis. 49, 1051–1060 (2009).
Arcaini, L. et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am. J. Hematol. 85, 46–50 (2010).
Locasciulli, A. et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood 90, 4628–4633 (1997).
Gigliotti, A. R., Fioredda, F. & Giacchino, R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J. Pediatr. Hematol. Oncol. 25, 184–192 (2003).
Poynard, T., Yuen, M. F., Ratziu, V. & Lai, C. L. Viral hepatitis C. Lancet 362, 2095–2100 (2003).
Pawlotsky, J. M. Use and interpretation of virological tests for hepatitis C. Hepatology 36 (Suppl. 1), 65–73 (2002).
Liang, R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113, 3147–3153 (2009).
Francisci, D. et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 38, 58–61 (2010).
Peffault de Latour, R. et al. Allogeneic hematopoietic cell transplant in HCV-infected patients. J. Hepatol. 48, 1008–1017 (2008).
Keeffe, E. B. Hepatitis B virus reactivation with chemotherapy: diagnosis and prevention with antiviral prophylaxis. Rev. Gastroenterol. Disord. 4, 46–48 (2004).
Fong, T. L. et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 107, 196–199 (1994).
Ciesek, S. et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 138, 1875–1884 (2010).
Magy, N. et al. Effects of corticosteroids on HCV infection. Int. J. Immunopharmacol. 21, 253–261 (1999).
Ennishi, D. et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am. J. Hematol. 83, 59–62 (2008).
Akiyama, H. et al. Effects of cyclosporin A on hepatitis C virus infection in bone marrow transplant patients. Bone Marrow Transplantation Team. Bone Marrow Transplant. 20, 993–995 (1997).
Anoop, P., Wotherspoon, A. & Matutes, E. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. Br. J. Haematol. 148, 484–486 (2010).
Gutierrez, M. L. et al. Cumulative dose of rituximab is a risk factor of HBV reactivation [abstract]. Hepatology 54 (Suppl. 1), a507 (2011).
Hsieh, C. Y. et al. Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma. J. Clin. Oncol. 26, 2584–2586 (2008).
Mahale, P. & Torres, H. A. Changes in hepatitis C virus RNA levels in cancer patients undergoing chemotherapy or immunosuppressive therapy. Presented at the 49th Annual Meeting of the Infectious Diseases Society of America (Boston, Massachusetts, 2011).
Ennishi, D. et al. Does rituximab really induce hepatitis C virus reactivation? J. Clin. Oncol. 26, 4695–4696 (2008).
Foran, J. M. Hepatitis C in the rituximab era. Blood 116, 5081–5082 (2010).
Boyle, S. & Reid, E. Viral reactivation and clinical hepatitis in patients with hepatitis C who receive rituximab as part of chemotherapy for treatment of lymphoma: A case series [abstract]. J. Clin. Oncol. 28 (Suppl.) e18559 (2010).
Sansonno, D. et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101, 3818–3826 (2003).
Torres, H., Mahale, P., Ying, J. & Kontoyiannis, D. P. Rituximab and gemcitabine are associated with acute exacerbation of chronic hepatitis C virus infection in patients with cancer [abstract]. Hepatology 54 (Suppl. 1), a1732 (2011).
Coppola, N. et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig. Liver Dis. 44, 49–54 (2012).
Ferri, C., Govoni, M. & Calabrese, L. The A, B, Cs of viral hepatitis in the biologic era. Curr. Opin. Rheumatol. 22, 443–450 (2010).
Cansu, D. U., Kalifoglu, T. & Korkmaz, C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J. Rheumatol. 35, 421–424 (2008).
Mahale P., Kaseb A., Davila M. & Torres H. A. The effect of transcatheter arterial chemoembolization on hepatitis C virus kinetics in patients with HCV associated hepatocellular carcinoma [abstract]. J. Clin. Oncol. 29 (Suppl.), e14578 (2011).
Maruta, A. et al. Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation. Bone Marrow Transplant. 13, 417–422 (1994).
Ljungman, P. et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 86, 1614–1618 (1995).
Kawatani, T., Tajima, F., Ishiga, K., Suou, T. & Kawasaki, H. Liver dysfunction in patients with acute myelogenous leukemia: studies on patients not infected with hepatitis C virus during intense therapy. J. Med. 29, 45–56 (1998).
Kawatani, T., Suou, T., Tajima, F., Ooi, S. & Kawasaki, H. Hepatitis C virus infection in acute leukemia with liver dysfunction. Eur. J. Haematol. 51, 254–255 (1993).
Besson, C. et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J. Clin. Oncol. 24, 953–960 (2006).
Gruber, A., Lundberg, L. G. & Bjorkholm, M. Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy. J. Intern. Med. 234, 223–225 (1993).
Firpi, R. J. & Nelson, D. R. Management of viral hepatitis in hematologic malignancies. Blood Rev. 22, 117–126 (2008).
Visco, C. et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann. Oncol. 17, 1434–1440 (2006).
Torres, H. A. et al. Hepatitis C virus infection in cancer patients: the story of a forgotten population. Presented at the 48th Annual Meeting of the Infectious Diseases Society of America (Vancouver, Canada, 2010).
Huang, J. F. et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis C patients with hepatocellular carcinoma post curative therapies—a multicenter prospective trial. J. Hepatol. 54, 219–226 (2011).
Ghany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L. & Seeff, L. B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54, 1433–1444 (2011).
Torres, H. A. et al. Hepatitis C clinic operated by infectious disease at a comprehensive cancer center—help is on the way. Clin. Infect.Dis. (in press).
Papaevangelou, V. et al. Hepatitis C treatment concomitant to chemotherapy as “salvage” therapy in children with hematologic malignancies. Pediatr. Infect. Dis. J. 29, 277–280 (2010).
Tomblyn, M. et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transplant. 15, 1143–1238 (2009).
Ghany, M. G., Strader, D. B., Thomas, D. L. & Seeff, L. B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335–1374 (2009).
Moradpour, D., Penin, F. & Rice, C. M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5, 453–463 (2007).
Gravitz L. Introduction: a smouldering public-health crisis. Nature 474, S2–S4 (2011).
Acknowledgements
We thank Stephanie P. Deming, scientific editor at the Department of Scientific Publications at the MD Anderson Cancer Center, for editorial assistance. No funding sources were involved in the writing of this Review or the decision to submit the Review for publication.
Author information
Authors and Affiliations
Contributions
Both authors researched data for the article, made substantial contributions to the discussion of content, wrote the article, and reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
H. A. Torres declares he is a consultant for Astellas, Merck, Vertex. M. Davila declares no competing interests.
Rights and permissions
About this article
Cite this article
Torres, H., Davila, M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 9, 156–166 (2012). https://doi.org/10.1038/nrclinonc.2012.1
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.1
This article is cited by
-
Akutes Leberversagen
Wiener klinisches Magazin (2019)
-
Hepatitis B and C Virus Reactivation Patterns in a Romanian Cohort of Patients with Chronic Lymphoproliferative Disorders
Indian Journal of Hematology and Blood Transfusion (2019)
-
Akutes Leberversagen
Medizinische Klinik - Intensivmedizin und Notfallmedizin (2018)
-
Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network
Digestive Diseases and Sciences (2018)
-
Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs
Scientific Reports (2016)